There are no new diabetes drug approvals and no new safety communications today. The regulatory sweep returned only supplemental applications to products already on the market — Jentadueto and Jentadueto XR, Trijardy XR, Synjardy and Synjardy XR, Zituvimet and Zituvimet XR, all existing metformin combinations, plus a supplement to Inpefa earlier this month. None of them is a new molecule and none carries a new safety signal. The most consequential recent decision remains the 2026 AHA/ACC dyslipidaemia guideline, and nothing today changes it. So the substantive item is a guideline analysis rather than an approval.
That analysis is a cross-sectional study of 4,366 adults aged 30 to 79 without known cardiovascular disease in the US national health survey, weighted to represent 154.5 million people, comparing statin eligibility under the 2026 guideline with the 2018 one. Under the new guideline 87.5 million adults, or 56.6%, are eligible for primary prevention statins, of whom 21.5 million (13.9%) are newly eligible. More than 93% of those aged 70 to 79 qualify and 85% of those aged 60 to 69, against 11% of those aged 30 to 39. The newly eligible are younger and at lower risk: mean estimated 10-year risk of 3.1% against 6.1% for those already eligible.
For a diabetologist the practical point runs the other way. Diabetes already qualifies a patient for a statin without any risk calculation, so almost every adult in your clinic was eligible before and remains so. What is worth tracking is the move to lower LDL targets and to the PREVENT risk tool. In India the eligibility arithmetic does not transfer at all — risk equations built on US cohorts perform poorly in a younger, lower-BMI, higher-prevalence population, and RSSDI guidance already treats diabetes as high risk. The target discussion transfers; the population estimates do not.
- Check that every adult with diabetes in your clinic is on a statin or has a documented reason not to be — diabetes qualifies without any risk score.
- Record the LDL cholesterol value, not just 'on statin' — the direction of travel is towards lower targets.
- Do not apply US risk equations to Indian patients uncritically; they were derived in different cohorts.
- When a patient arrives newly told they need a statin, check the reason — low-risk primary prevention and diabetes are different conversations.
- Review claimed statin intolerance properly rather than accepting it; the eligible population is growing, not shrinking.
The statistics, in plain English
These are prevalence estimates from a survey sample scaled up to a whole population, so the intervals look narrow (56.6%, CI 54.2% to 58.9%) — but that precision describes the sampling, not any certainty about an individual patient. The number that matters clinically is the mean 10-year risk of the newly eligible group: 3.1% against 6.1% for those already eligible. Roughly halving the baseline risk roughly halves the absolute benefit of treating, even when the relative risk reduction from a statin is unchanged, so many more people must be treated to prevent one event in the new group. None of this arithmetic carries over to India, where baseline risk, age of onset and the underlying cohort data all differ.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free